This Phase 3 trial (Study SRK-015-003) is being conducted in patients ≥2 years old at Screening, who were previously diagnosed with later-onset spinal muscular atrophy (SMA) (i.e., Type 2 and Type 3 SMA) and are receiving an approved survival motor neuron (SMN) upregulator therapy (i.e., either nusinersen or risdiplam), to confirm the efficacy and safety of apitegromab as an adjunctive therapy to nusinersen and evaluate the efficacy and safety of apitegromab as an adjunctive therapy to risdiplam.
- Social Wall
- Trusted Resources
-
Trusted Resources Home
-
Education
Scientific literature & patient education texts -
People & Places
Healthcare providers, researchers, & advocates -
Community Center
Online groups, photo galleries, & blogs -
News & Meetings
Latest announcements & gatherings -
Videos & Visuals
Channels, infographics, & slides
-
- Clinical Trial Education
- my Account